Reldesemtiv is a Small Molecule owned by Cytokinetics, and is involved in 10 clinical trials, of which 8 were completed, and 2 are ongoing.
Reldesemtiv (CK-2127107) is a fast skeletal muscle troponin activator. It activates TNNC2, TNNI2 and TNNT3. Ca2+ binds to the N-terminal Ca2+ binding site of troponin C initiating a conformational change in troponin C, which catalyzes protein-protein associations activity. This activation, in turn, facilitates cross-bridge cycling, myofibrillar activation complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility.
The revenue for Reldesemtiv is expected to reach a total of $542m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Reldesemtiv NPV Report.
Reldesemtiv is originated and owned by Cytokinetics.
Reldesemtiv (CK-2127107) is under development for the treatment of amyotrophic lateral sclerosis. The drug candidate is administered through the oral route in the form of a tablet and suspension. It is a new molecule entity that acts on fast skeletal muscle troponin activator (FSTA). It was also under development for spinal muscular atrophy, movement disorders (frailty syndrome) in older patients and chronic obstructive pulmonary disease (COPD).
Cytokinetics is a biopharmaceutical company with a focus on the discovery, development, and commercialization of muscle activators and muscle inhibitors as potential treatments for debilitating diseases wherein muscle performance is affected. The company develops small molecule drug candidates designed to affect muscle function and contractility. Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It is also developing reldesemtiv, a fast skeletal muscle troponin activator, for the treatment of ALS patients. The company has licensing and collaboration agreements with Amgen, Ji Xing, and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$70.4 million for the fiscal year ended December 2021 (FY2021), an increase of 26.2% over FY2020. The operating loss of the company was US$186.3 million in FY2021, compared to an operating loss of US$93.9 million in FY2020. The net loss of the company was US$215.3 million in FY2021, compared to a net loss of US$127.3 million in FY2020. The company reported revenues of US$2.5 million for the third quarter ended September 2022, a decrease of 97.2% over the previous quarter.
Quick View – Reldesemtiv
|Highest Development Stage|